The specialist also added that the Pfizer vaccine is effective against the delta variant, but that newly infected people were vaccinated with the vaccine in January or February and the number of antibodies decreased during this time.
(latest news here)
Data from the United Kingdom and Israel shows the vaccine is more effective in preventing more severe symptoms of infection, even with low levels of antibody, by about 95 percent. Michael Dolstein announced that the company will soon publish research that processes Israeli data.
He said many countries, including Europeans, had already contacted them about a possible third vaccination, which he said was especially important for older adults.
Due to the new dose of Pfizer’s vaccine and the fact that there are still many people in the world who have not been vaccinated, the demand for the vaccine is likely to increase, so the company is trying to increase its production capacity.
The company aims to produce 3 billion doses of vaccine this year and 4 billion next year.
Albert Burla, Pfizer’s president and CEO, said in April that Pfizer’s vaccine syringes will likely need a third dose within 6 to 12 months after the first dose that maintains protection, and the vaccination will likely need an annual repeat.
(You may also be interested in: Alarming news came about the Sputnik V vaccine: the World Health Organization discovered a serious defect in one of the plants)